Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 96

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 96
---
,
and actual pricing will depend on multiple factors including clinical results, regulatory approval, reimbursement, adoption, and competition.

Epidemiology and Estimated Market Opportunity for Methicillin-Resistant Staphylococcus Aureus (MRSA), Including Vancomycin-Resistant (VRE) Cases

MRSA is a leading cause of hospital- and community-acquired
infections. The CDC estimates over 1.2 million MRSA infections annually in the U.S. with another 423,000 hospitalized patients colonized
with the bacteria [8]. While Vancomycin is standard therapy, resistance and treatment failures are increasing, prompting interest in
second-line options including liposomal Amphotericin B [9].

Our novel formulation of systemic Liposomal-Mupirocin
is positioned to target serious systemic MRSA infections, especially in Vancomycin-resistant or refractory cases.

Pricing Benchmark and Market Assumptions

| - | Liposomal Amphotericin B (per dose):                                                
 ~$120 (average worldwide without US)- ~$341 in the US [4], per course ~$1700-~4,700 |

| - | Assumed Liposomal Mupirocin IV pricing:                                                  
 ~$220 per dose, with a total course cost ranging from ~$1,540 to $3,000 depending on the 
 number of injections required. The exact dosage regimen and treatment duration remain to 
 be determined during the planned clinical trials.                                        |

| - | Assumed average pricing per course 
 for illustration purposes: ~$2,200 |

<div align='center'>60</div>

U.S. incidence of MRSA:

| - | Based on an estimated 32 invasive MRSA                                                      
 cases per 100,000 people [10], the U.S. (population ~330 million) has approximately 106,000 
 such cases annually                                                                         |

| - | U.S. Total Addressable Market TAM for invasive infections: |

| - | 106,000 × $2,200 = ~$230 million/year |

| - | Estimated annual revenue potential at 30% assumed realistic market          
 penetration over 5 years (U.S. Serviceable Obtainable Market): ~$70 million |

Global Total Addressable Market (TAM) assumptions rationale:

| - | We estimate the global market at roughly 3 times the size of the 
 U.S. market at around $690 million.                              |

| - | Estimated global annual realistic revenue potential at 20% market